Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study
Launched by ANHUI MEDICAL UNIVERSITY · Mar 22, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how certain brain blood vessel conditions, specifically symptomatic intracranial atherosclerotic stenosis (ICAS), can lead to problems with thinking and memory. Researchers want to learn more about the reasons behind these cognitive issues and how different treatments might help improve brain function in individuals with this condition. The study is currently recruiting participants, who can be between the ages of 65 and 74, and it is open to all genders.
To be eligible for the trial, participants should be able to understand the study and have no signs of severe brain dysfunction. They need to have been diagnosed with significant narrowing or blockage of the brain's arteries and have a history of temporary stroke-like symptoms or mild strokes. However, those with a history of severe strokes, major psychiatric disorders, or certain medical devices implanted in their bodies are not eligible. Participants can expect to undergo assessments and possibly receive different treatment options while helping researchers learn more about cognitive impairment in this patient group. Your involvement could contribute to better understanding and treatment of cognitive issues linked to brain blood vessel conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Non-illiterates, no symptoms and signs of central nervous system dysfunction, head CT or head MRI showed normal cerebral parenchyma or old lacunar cerebral infarction, and non-thalamus, frontal lobe, temporal lobe and other cognitively related infarction;
- • 2. TCD\\CTA\\MRA\\DSA present intracranial artery stenosis (50% or more) or occlusion;
- • 3. History of vascular-related TIA and acute cerebral infarction (more than 2 weeks after lastest), and NIHSS score was less than or equivalent to 4 points at the time of enrollment;
- Exclusion Criteria:
- • 1. History of stroke,transient ischemic attack,seizures or unexplained loss of consciousness.
- • 2. Organic brain defects on T1 or T2 images.
- • 3. Any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder).
- • 4. Implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator. History of substance abuse within the last 6 months
About Anhui Medical University
Anhui Medical University, a leading institution in medical education and research in China, is dedicated to advancing healthcare through innovative clinical trials and rigorous scientific inquiry. With a robust infrastructure and a commitment to ethical research practices, the university fosters collaboration among multidisciplinary teams to explore novel therapeutic interventions and improve patient outcomes. Its focus on translational medicine and public health reflects a deep commitment to addressing pressing health challenges both locally and globally. Through its clinical trial initiatives, Anhui Medical University aims to contribute significantly to the evidence base in medicine and enhance the quality of care provided to diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hefei, Anhui, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported